Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 692

1.

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH.

Blood. 2002 Dec 15;100(13):4298-302. Epub 2002 Aug 15.

2.

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P.

Blood. 1998 Oct 15;92(8):2712-8.

3.

Long-term survey of outcome in acute promyelocytic leukemia.

Hu J, Shen Z, Sun H, Wu W, Li X, Sun G, Wang Z.

Chin Med J (Engl). 2000 Feb;113(2):107-10.

PMID:
11775530
4.

All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.

Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, et al.

Blood. 1995 Mar 1;85(5):1202-6.

6.

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L.

Blood. 1999 Aug 15;94(4):1192-200.

7.

Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

Asou N, Adachi K, Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake H, Ohno R.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71.

PMID:
11587370
8.

All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).

Chim CS, Kwong YL, Liang R, Chu YC, Chan CH, Chan LC, Wong KF, Chan TK.

Hematol Oncol. 1996 Sep;14(3):147-54.

PMID:
9119359
9.

[Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].

Xu XJ, Shi SW, Tang YM, Song H, Yang SL, Wei J, Xu WQ, Pan BH, Chen YH, Zhao FY, Shen HQ, Qian BQ, Zhang LY, Ning BT.

Zhongguo Dang Dai Er Ke Za Zhi. 2007 Feb;9(1):28-33. Chinese.

PMID:
17306073
11.

[Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].

Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.

Srp Arh Celok Lek. 1995 Nov-Dec;123(11-12):279-85. Serbian.

PMID:
16296239
12.

All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).

Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Sakamaki H, Tsubaki K, Saito K, Ohno R.

Cancer Chemother Pharmacol. 1997;40 Suppl:S30-5.

PMID:
9272131
13.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group.

J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20.

PMID:
17116939
14.

Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.

de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P.

J Clin Oncol. 2004 Apr 15;22(8):1404-12.

PMID:
15084614
15.

All-trans-retinoic acid in acute promyelocytic leukemia.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH.

N Engl J Med. 1997 Oct 9;337(15):1021-8. Erratum in: N Engl J Med 1997 Nov 27;337(22):1639.

16.

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P; European APL Group.

Br J Haematol. 2000 Dec;111(3):801-6.

PMID:
11122141
17.

All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases.

Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, et al.

Blood. 1992 Nov 1;80(9):2176-81.

18.

Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy.

Thomas X, Anglaret B, Thiebaut A, Belhabri A, Treille-Ritouet D, Fiere D, Archimbaud E.

Ann Hematol. 1997 Nov-Dec;75(5-6):195-200.

PMID:
9433375
19.

Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.

Advani SH, Nair R, Bapna A, Gladstone B, Kadam P, Saikia TK, Parekh PM, Gopal R, Nair CN.

Am J Hematol. 1999 Feb;60(2):87-93.

20.

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L.

J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.

PMID:
19414681

Supplemental Content

Support Center